LEE M ELLIS to Angiogenesis Inhibitors
This is a "connection" page, showing publications LEE M ELLIS has written about Angiogenesis Inhibitors.
Connection Strength
4.636
-
Predictive biomarkers for bevacizumab: are we there yet? Clin Cancer Res. 2013 Jun 01; 19(11):2824-7.
Score: 0.266
-
Antiangiogenic therapy--evolving view based on clinical trial results. Nat Rev Clin Oncol. 2012 02 14; 9(5):297-303.
Score: 0.246
-
Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer. J Clin Oncol. 2012 Feb 01; 30(4):345-7.
Score: 0.243
-
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010 Apr; 11(4):373-82.
Score: 0.214
-
Cancer: The nuances of therapy. Nature. 2009 Mar 19; 458(7236):290-2.
Score: 0.201
-
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res. 2008 Oct 15; 14(20):6371-5.
Score: 0.195
-
Bevacizumab beyond progression: does this make sense? J Clin Oncol. 2008 Nov 20; 26(33):5313-5.
Score: 0.195
-
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008 Aug; 8(8):579-91.
Score: 0.191
-
Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 2008 May-Jun; 14(3):170-7.
Score: 0.189
-
Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006 Oct; 33(5 Suppl 10):S1-7.
Score: 0.169
-
Bevacizumab. Nat Rev Drug Discov. 2005 May; Suppl:S8-9.
Score: 0.154
-
Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol. 2004 Dec; 31(6 Suppl 17):3-9.
Score: 0.149
-
Preclinical data targeting vascular endothelial growth factor in colorectal cancer. Clin Colorectal Cancer. 2004 Oct; 4 Suppl 2:S55-61.
Score: 0.148
-
Current overview of angiogenesis inhibitors. Clin Adv Hematol Oncol. 2004 Aug; 2(8):494-6, 520.
Score: 0.146
-
Antiangiogenic therapy at a crossroads: clinical trial results and future directions. J Clin Oncol. 2003 Dec 01; 21(23 Suppl):281s-283s.
Score: 0.139
-
Antiangiogenic therapy: more promise and, yet again, more questions. J Clin Oncol. 2003 Nov 01; 21(21):3897-9.
Score: 0.138
-
Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol. 2003 Aug; 10(7):722-33.
Score: 0.136
-
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 2003 May 01; 63(9):2079-87.
Score: 0.134
-
Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003 Apr 20; 104(4):496-503.
Score: 0.133
-
Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol Med. 2003 Feb; 9(2):53-8.
Score: 0.131
-
A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am Surg. 2003 Jan; 69(1):3-10.
Score: 0.131
-
Antiangiogenic therapy targeting factors that enhance endothelial cell survival. Semin Oncol. 2002 Jun; 29(3 Suppl 11):96-103.
Score: 0.126
-
Synopsis of angiogenesis inhibitors in oncology. Oncology (Williston Park). 2002 May; 16(5 Suppl 4):14-22.
Score: 0.125
-
Mechanisms of anti-angiogenic tyrosine kinase inhibition on wound healing--the obvious and not so obvious. Cancer Biol Ther. 2002 Mar-Apr; 1(2):127-9.
Score: 0.123
-
Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016 Jul 30; 388(10043):518-29.
Score: 0.081
-
Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer. 2003 Aug; 3(2):85-8.
Score: 0.068
-
Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin Cancer Res. 2009 Nov 15; 15(22):6763-70.
Score: 0.052
-
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol. 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10.
Score: 0.047
-
Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology. 2005 Oct; 237(1):151-8.
Score: 0.040
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005 Feb 10; 23(5):1011-27.
Score: 0.037
-
Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens? Clin Colorectal Cancer. 2004 Oct; 4 Suppl 2:S69-73.
Score: 0.037
-
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther. 2004 Sep; 3(9):1041-8.
Score: 0.037
-
Vascular endothelial growth factor receptors: expression and function in solid tumors. Clin Adv Hematol Oncol. 2004 Jan; 2(1):37-45.
Score: 0.035
-
Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech. 2003 Feb 01; 60(2):199-207.
Score: 0.033
-
Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002 Sep 15; 20(18):3792-803.
Score: 0.032
-
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002 Sep 15; 20(18):3804-14.
Score: 0.032
-
Advances in the treatment of liver tumors. Curr Probl Surg. 2002 May; 39(5):449-571.
Score: 0.031
-
The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biol. 2002 Apr; 12(2):105-12.
Score: 0.031
-
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008 Nov 10; 26(32):5254-60.
Score: 0.012
-
Induction of apoptosis by the green tea flavonol (-)-epigallocatechin-3-gallate in human endothelial ECV 304 cells. Anticancer Res. 2002 Nov-Dec; 22(6A):3373-8.
Score: 0.008